Group 1 - The seminar on the research results of "Masitide Dreams Series" was held in Beijing, focusing on two Phase III clinical studies conducted by the Chinese endocrinology and metabolism experts in collaboration with Innovent Biologics [2] - The studies published in the journal Nature include DREAMS-1, which examines monotherapy in type 2 diabetes patients, and DREAMS-2, which investigates the combination with oral hypoglycemic agents, both based on data from Chinese patients [2] - There is a growing demand among Chinese consumers for weight loss solutions that not only control weight but also address metabolic issues such as fatty liver, hypertension, and hyperlipidemia, highlighting the need for treatments that promote fat burning and liver protection [2] Group 2 - The number of type 2 diabetes patients in China is large and increasing, with a trend of earlier onset and rising rates of overweight and obesity, indicating a need for treatment strategies that address both blood sugar control and weight management [3] - The clinical treatment approach for type 2 diabetes is shifting from solely focusing on blood sugar levels to a comprehensive management of multiple metabolic risks [3] - Innovent Biologics aims to provide diverse solutions for different patient groups, supporting tiered weight management and achieving precise treatment to meet the public's pursuit of a better quality of life [3]
“玛仕度肽Dreams系列研究成果研讨会”在北京举办